Click on a filter below to refine your search. Remove a filter to broaden your search.
Baricitinib plus remdesivir was linked to a reduced risk of death and progression to invasive mechanical ventilation.
In New England and the Pacific, prevalence tended to be lower, whereas higher prevalence was seen in the South, Midwest and West.
The greatest increase in utilization was seen for veterans aged 85 years and older (6.1 visits) versus those aged 20 to 44 years (4.8 visits).
The findings were clinically significant at three and 12 months versus usual care.
Vaccine effectiveness was 49% at 60 to 119 days after vaccination among tests exhibiting spike gene target failure.
No reason other than mild symptoms was given for almost half of patients at high risk for progression who were not offered treatment.
The risk for death was found to be exacerbated by comorbidities.
Associations were seen for working on the hospital unit, mood disturbances and sleep disturbances with depression and anxiety.
And patients aged ≥60 years hospitalized with RSV are more likely to have severe illness than those with COVID-19 or influenza.
Hospital admissions increased only for adolescents, whereas a decrease was seen for adults, especially those aged 41 to 105 years.